Actuate Therapeutics Reports Third Quarter 2026 Financial Results
Actuate Therapeutics reported its financial results for the third quarter of 2026, highlighting a reduction in operating losses compared to the same period last year.
Stocks · News reference
HC Wainwright & Co. has revised its price target for Actuate Therapeutics, Inc. from $15 to $10 while maintaining a 'Buy' rating on the stock.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Actuate Therapeutics reported its financial results for the third quarter of 2026, highlighting a reduction in operating losses compared to the same period last year.
Actuate Therapeutics announced new preclinical data demonstrating the antitumor and immune activation activity of its oral elraglusib tablet in advanced melanoma models at the ENA 2026 symposium.
Actuate Therapeutics has received a Notice of Allowance from the USPTO for its patent application regarding oral dosage forms of its lead investigational drug, elraglusib.
Filed: 2026-10-30 AccNo: 0001683168-26-008193 Size: 207 KB Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Actuate Therapeutics, Inc. has priced an underwritten public offering of its securities to raise $11.0 million in gross proceeds.